# Thabor Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thabor-therapeutics

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.thabor-tx.com
- Total disclosed funding: $1.2M
- Latest round: Seed (Jul 27, 2021)
- Investors on record: 1

## About

Based in France, and founded in 2021 by Eric Chevet, Eric Ogier – Denis, and Xavier Treton, Thabor Therapeutics, is the provider of drugs for the cure of human mucosal inflammatory diseases. In July 2022, Thabor Therapeutics raised EUR 2 million in seed funding led by new investor Bpifrance. As of 2022, the company is headed by Jeremie Mariau as CEO.

The company develops the treatment of chronic mucosal inflammatory diseases, in particular Inflammatory Bowel Disease (IBD) such as Crohn’s disease and ulcerative colitis. 

The company will use the July 2022 funding to boost its research and development programs to support the industrial development of its monoclonal antibodies and an IND (Investigational New Drug) application.

## Funding rounds

- Seed, Jul 27, 2021, $1.2M — AdBio Partners

## Investors

- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed